



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number: **0 624 374 A1**

12

## EUROPEAN PATENT APPLICATION

21 Application number: **94107051.8**

51 Int. Cl.<sup>5</sup>: **A61K 35/38, A61K 31/73**

22 Date of filing: **05.05.94**

30 Priority: **10.05.93 IT BO930205**

43 Date of publication of application:  
**17.11.94 Bulletin 94/46**

84 Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL  
PT SE**

71 Applicant: **ALFA WASSERMANN S.p.A.**  
**Contrada Sant'Emidio**  
**I-65020 Alanno Scalo (Pescara) (IT)**

72 Inventor: **Marchi, Egidio**  
**Via Don Ercolani n. 3**  
**I-40033 Casalecchio di Reno (Bologna) (IT)**  
Inventor: **Tamagnone, Gianfranco**  
**Via Ronzani n. 55**  
**I-40033 Casalecchio di Reno (Bologna) (IT)**

74 Representative: **Kraus, Walter, Dr. et al**  
**Patentanwälte Kraus, Weisert & Partner**  
**Thomas-Wimmer-Ring 15**  
**D-80539 München (DE)**

54 Use of sulodexide and of medicines containing it for the treatment of diabetic nephropathy.

57 The use of sulodexide, a glycosaminoglycan of natural origin extracted from mammalian intestinal mucosa, and of medicines containing it in the treatment of patients suffering from nephropathy of diabetic origin constitutes the object of the present invention.

The effectiveness of sulodexide has been shown by the significative decrease of the albuminuria in microalbuminuric and macroalbuminuric diabetic patients treated with pharmaceutical compositions administered by oral or intramuscular route containing therapeutically effective amounts of drug.

**EP 0 624 374 A1**

Rank Xerox (UK) Business Services

BNSDOCID: <EP\_0624374A1\_I\_>

ATTORNEY DOCKET NUMBER: 9457-023  
SERIAL NUMBER: 09/873,234  
REFERENCE: CW

**BACKGROUND OF THE INVENTION**

The use of glycosaminoglycans, and particularly of heparins, in anticoagulant and antithrombotic therapies is well known. Sulodexide is a glycosaminoglycan of natural origin, extracted from mammalian intestinal mucosa, possessing a sulfation degree and an anticoagulant activity lower than those of heparin, as shown by Radhakrishnamurthy B. *et al.*, *Atherosclerosis* 31 217-229, (1978). It is marketed under the trademark **VESSEL DUE P** for the treatment of vascular pathologies with thrombotic risk like periferal arteriopathies, as shown by Crepaldi G. *et al.*, *Atherosclerosis*, 81, 233, (1990), cardiovascularopathies, as shown by Tamarin A. *et al.*, *Medical Praxis*, 8 1, (1987), cerebrovasculopathies, as shown by Sozzi C., *Eur. Rev. Med. Pharmacol. Sci.*, 6, 295, (1984) and venous pathologies of the lower limbs, as shown by Cospite M. *et al.*, *Acta Therapeutica*, 18, 149, (1992).

Kanwar Y.S. *et al.*, *Sem. Nephrol.*, 5, 307, (1985) and Groggel G. C. *et al.*, *Kidney Int.*, 33, 517, (1988), recently produced evidence of the probable role of glycosaminoglycans in helping the integrity and the functioning of the renal cells.

Moreover, Canfield J. P. *et al.*, *Lab. Invest.*, 39, 505, (1978), previously showed a decrease of glycosaminoglycans of membrane in many conditions of nephropathy, while Baggio B. *et al.*, *Nephron.*, 43, 187, (1986) showed this decrease through an increased urinary elimination of glycosaminoglycans in diabetic, non-albuminuric, patients. This increased excretion of glycosaminoglycans in diabetic nephropathies, shown also by Fartasarathy N. *et al.*, *Diabetes*, 31, 738, (1982), recently suggested to Gambaro G. *et al.*, *Metabolism* 38, 419, (1989), the possibility of resorting to the determination of the amount of glycosaminoglycans excreted by urinary route as an analytical method more reliable than the microalbuminuria in the recognition of the nephropathy of diabetic origin.

Lastly, Diamond J.R. *et al.*, *Renal Physiol.*, 9, 366, (1986) and Parkerson M.B. *et al.*, *J. Clin. Invest.*, 81, 69, (1988), showed in animals the potential protective effect of heparin and its derivatives in models of experimental nephropathy not related to diabetic nephropathy, like chronic nephrosis from aminoglycosides and renal pathologies resulting from the subtotal renal ablation in the rat.

Lastly, the possibility to use heparin, low molecular weight heparin fractions, chemically modified heparins or low molecular weight dermatan sulfate in the treatment of the diabetic nephropathy and neuropathy has been described in the European patent publication EP 0513513. This possibility of therapeutic use was shown by means of pharmacological tests on animals: diabetes was caused by streptozotocin in Sprague Dawley male albino rats and the diabetic rats were treated with the above mentioned glycosaminoglycans whose effectiveness was determined on the basis of some parameters like the diminution of the albuminuria and of the thickness of the basal glomerular membrane and the increase of the glomerular anionic charges.

**DESCRIPTION OF THE INVENTION**

The therapeutic use of sulodexide, a glycosaminoglycan of natural origin extracted from mammalian intestinal mucosa possessing a sulfation degree and an anticoagulant activity lower than those of heparin, and of the medicines containing it in the treatment of patients suffering from microalbuminuria or macroalbuminuria, i.e. showing a more or less substantial increase of albumin in the urines, until 200 mcg/min for the microalbuminuric patients and more than 200 mcg/min for the macroalbuminuric patients, constitutes the object of the present invention. The present invention is an overcoming of the teachings of the prior art because a true therapeutic effectiveness on man of a drug widely used for a long period of time in pathologies completely different from the nephropathy of diabetic origin has been clinically demonstrated.

This pathology affects from 30% to 40% of the patients suffering from insulin dependent type I diabetes and causes in time a chronic renal insufficiency that often obliges the patient to submit himself to the dialysis treatment.

The diabetic nephropathy is a clinically well defined pathology characterized by proteinuria, hypertension, edema and renal insufficiency and generally occurs in patients suffering from diabetes from more than ten years. The diabetic nephropathy differentiates in three types, on the basis of the histopathologic characteristics that distinguish it: 1) glomerulosclerosis, 2) modification of the vascular structure, mainly in the small arterioles and 3) tubulointerstitial disease.

The more characteristic aspect of the diabetic nephropathy is the glomerular injury, detectable by the enlargement of the mesangium and by the thickening of the basal membrane, which often looks like a diffuse cicatrization of the whole glomerule.

The first clinical evidence of the diabetic nephropathy is given by the presence of albuminuria in the urines, albuminuria that takes the name of microalbuminuria when the albumin amount in the urines is comprised between 20 and 200 mcg/min and of macroalbuminuria when this amount exceeds 200 mcg/min.

The therapeutic protections used at present for the treatment of diabetic patients with complications of albuminuria and nephropathy are:

- 1) Use of ACE-inhibitors antihypertensive drugs;
- 2) Control of glycemic values;
- 3) Lypoproteic diet.

No drug, till now, has been able to lower in a substantial way the levels of albuminuria in diabetic patients and only the ACE-inhibitors drugs have given encouraging results.

It has now been found that the administration of pharmaceutical compositions containing therapeutically effective amounts of sulodexide to diabetic patients with microalbuminuria or macroalbuminuria causes a remarkable and significative lowering in the urinary excretion of albumin.

Moreover it has been ascertained that the treatment with sulodexide allowed to keep substantially unchanged the renal functioning also four months after the cessation of the treatment as the glomerular filtrate, measured before the beginning of the treatment with sulodexide and four months after the end of the treatment, remained substantially unchanged.

All kinds of pharmaceutical compositions administrable by oral, subcutaneous, intramuscular or intravenous routes can be advantageously used in carrying out the present invention. Tablets, controlled release tablets, gastroresistant tablets, capsules, gastroresistant capsules, granulates or syrups are the pharmaceutical compositions administrable by oral route preferred in the realization of the present invention.

The dosage, function of the body weight and the seriousness of the pathology, is comprised between 500 L.R.U. (lipoprotein lipase releasing units) and 1500 L.R.U. a day.

The therapeutical effectiveness of sulodexide has been evaluated in two clinical studies. The first test was carried out on ten ambosexual diabetic patients, partly microalbuminuric and partly macroalbuminuric, to whom 1000 L.R.U. of sulodexide a day were administered for 60 consecutive days under form of two 250 L.R.U. capsules administered twice a day of **VESSEL DUE F®**.

The diabetic patients continued the pre-existent antihypertensive therapy based on calcium-antagonist and/or ACE-inhibitor drugs throughout the treatment with sulodexide.

The therapeutic results of the treatment with sulodexide, reported in example 1, show how 8 out of 10 diabetic patients, 4 microalbuminuric and 4 macroalbuminuric, obtained a significative lowering in the albumin excretion, with an average decrease respectively equal to 44% and 35% and how only two microalbuminuric patients did not get any improvement. Moreover no substantial change of the glomerular renal filtrate was noted four months after the end of the treatment with sulodexide. This fact shows how the treatment with sulodexide made possible to keep substantially unaltered the renal functionality for a medium period of time after the end of the treatment.

The second clinical test was carried out on five ambosexual diabetic patients, three microalbuminuric and two macroalbuminuric, to whom 600 L.R.U. of sulodexide a day were administered by intramuscular route for 21 consecutive days under form of one 600 L.R.U. vial of **VESSEL DUE F®**. The diabetic patients continued the pre-existent antihypertensive therapy based on calcium-antagonist and/or ACE-inhibitor drugs throughout the treatment with sulodexide. The therapeutic results of the treatment with sulodexide, reported in example 2, show a significative lowering in the albumin excretion of all the five patients.

The examples of clinical tests are given to further illustrate the invention and cannot be taken as a limitation of the invention itself.

#### EXAMPLE 1

##### Treatment of nephropathic diabetic patients with capsules containing sulodexide.

Ten ambosexual adult consentient diabetic patients, six with microalbuminuria and four with macroalbuminuria, were treated with sulodexide at the Institute of Internal Medicine of the University of Padua. The albuminuria of the ten patients was evaluated every day for three days before the beginning of the treatment with sulodexide and its average value was calculated; also the value of the glomerular filtrate was assessed. Then two 250 L.R.U. capsules of **VESSEL DUE F®** were given to the patients twice a day for 60 consecutive days while keeping the pre-existent antihypertensive therapy based on calcium-antagonist and/or ACE-inhibitor drugs for the whole time.

The albuminuria was evaluated again at the end of the therapy while the value of the glomerular filtrate was assessed again four months after the end of the treatment in order to verify the renal functionality.

The clinical results showing the effectiveness of the treatment with sulodexide are summarized in the following three tables. **Table 1** refers to all the microalbuminuric patients, **table 2** refers to patients who favourably responded to the treatment with sulodexide and **table 3** refers to macroalbuminuric patients.

TABLE 1

Patient	Sex	Age (years)	Weight (Kg)	Antihypertensive therapy	Albumin before the treatment (mcg/min)	Albumin after 60 days of treatment (mcg/min)	Glomerular filtration before the treatment (ml/min)	Glomerular filtration four months after the end of the treatment (ml/min)
1	M	54	66	Calcium-antagonist drugs	59.17	86.00	106.34	106.00
2	M	50	104	Calcium-antagonist plus ACE-inhibitor drugs	199.82	81.77	121.00	125.80
3	M	60	95	ACE-inhibitor drugs	98.86	86.12	98.57	102.30
4	F	40	76	Calcium-antagonist plus ACE-inhibitor drugs	65.55	114.98	86.00	90.60
5	M	48	76	Calcium-antagonist drugs	47.82	33.10	86.56	85.54
6	F	49	78	Calcium-antagonist plus ACE-inhibitor drugs	44.60	20.40	121.70	119.6
Average $\bar{X} \pm \text{s.e.}$		$50.1 \pm 2.6$	$82.5 \pm 5.6$		$85.9 \pm 23.6$	$70.3 \pm 14.4$	$103.3 \pm 6.3$	$104.9 \pm 6.2$

TABLE 2

Patient	Sex	Age (years)	Weight (Kg)	Antihypertensive Therapy	Albumin before the treatment (mcg/min)	Albumin after 60 days of the treatment (mcg/min)
2	M	50	104	Calcium-antagonist plus ACE-inhibitor drugs	199.82	81.77
3	M	60	95	ACE-inhibitor drugs	98.86	86.12
5	M	48	76	Calcium-antagonist drugs	47.82	33.10
6	F	49	78	Calcium-antagonist plus ACE-inhibitor drugs	44.60	20.40
Average $\bar{X} \pm s.e.$		$51.7 \pm 2.7$	$88.2 \pm 6.7$		$97.7 \pm 18.1$	$55.3 \pm 16.7$

TABLE 3

Patient	Sex	Age (years)	Weight (Kg)	Antihypertensive therapy	Albumin before the treatment (mcg/min)	Albumin after 60 days of treatment (mcg/min)	Glomerular filtration before the treatment (ml/min)	Glomerular filtration four months after the end of the treatment
7	F	63	81	Calcium-antagonist drugs	307.63	205.97	72.28	71.24
8	M	39	63	Calcium-antagonist drugs	2402.78	1215.28	94.42	70.80
9	F	69	85	Calcium-antagonist plus ACE-inhibitor drugs	416.67	135.85	72.58	68.31
10	F	44	81	Calcium-antagonist plus ACE-inhibitor drugs	1564.01	1493.06	52.48	55.32
Average $\bar{X} \pm \text{s.e.}$		$53.7 \pm 7.2$	$77.5 \pm 4.9$		$1172.76 \pm 249.4$	$762.5 \pm 346.5$	$72.9 \pm 8.5$	$66.4 \pm 3.75$

**EXAMPLE 2**

**Treatment of nephropathic diabetic patients by intramuscular route with vials containing sulodexide**

5

Five ambosexual adult consentient diabetic patients, three with microalbuminuria and two with macroalbuminuria, were treated with sulodexide at the Institute of Internal Medicine of the University of Padua.

The albuminuria of the five patients was evaluated every day for three days before the beginning of the treatment with sulodexide and its average value was calculated.

10

One vial of VESSEL DUE F®, containing in 2 ml of solution 600 L.R.U. of sulodexide, was given by intramuscular route to the patients for 21 consecutive days while keeping the pre-existent antihypertensive therapy based on calcium-antagonist and/or ACE-inhibitor drugs for the whole time.

At the end of the therapy the albuminuria was evaluated again and the clinical results showing a significant decrease of the albuminuria, from 42.86% to 94.72%, are summarized in the following table 4.

15

20

25

30

35

40

45

50

55

TABLE 4

Patient	Sex	Age (years)	Weight (Kg)	Antihypertensive Therapy	Albumin before the treatment (mcg/min)	Albumin after 21 days of the treatment (mcg/min)
1	F	65	63	Calcium-antagonist drugs	30.90	15.28
2	F	23	71	No antihypertensive therapy	31.60	1.67
3	F	40	76	Calcium-antagonist plus ACE-inhibitor drugs	99.40	56.80
4	M	53	100	Calcium-antagonist drugs	639.93	324.38
5	F	44	81	Calcium-antagonist plus ACE-inhibitor drugs	2222.20	346.25
Average X $\pm$ s.e.		45 $\pm$ 7	78.2 $\pm$ 6.2		604.81 $\pm$ 420.15	148.88 $\pm$ 76.73

## 55 Claims

1. Use of sulodexide in the manufacture of a medicine for the treatment of diabetic nephropathy.



EP 0 624 374 A1

2. Use according to claim 1 characterized in that the medicine is a pharmaceutical composition admin-  
istrable by oral route.
3. Use according to claim 2 characterized in that the pharmaceutical composition is selected from tablets,  
5 controlled release tablets, gastroresistant tablets, capsules, gastroresistant capsules, granulates and  
syrups.
4. Use according to claim 1 characterized in that the medicine is a pharmaceutical composition admin-  
istrable by subcutaneous, intramuscular or intravenous route.
- 10 5. Use according to claim 1 characterized in that the dosage is comprised between 500 L.R.U. and 1500  
L.R.U. a day.

15

20

25

30

35

40

45

50

55



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 94107051.8
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.5)
X, D	<u>EP - A - 0 513 513</u> (ALFA WASSERMANN S.P.A.) * Claim 1; example 1 * --	1, 4	A 61 K 35/38 A 61 K 31/73
A	<u>EP - A - 0 497 162</u> (ALFA WASSERMANN S.P.A.) * Claims 1-3 * ----	1-3	
			TECHNICAL FIELDS SEARCHED (Int. CL.5)
			A 61 K
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 24-08-1994	Examiner BÖHM
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EP FORM 150 (01/87) (P0401)